Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

被引：17

作者：

Buehler, A. ^{[1
]}

Wendtner, C-M ^{[2
,3
]}

Kipps, T. J. ^{[4
]}

Rassenti, L. ^{[4
]}

Fraser, G. A. M. ^{[5
]}

Michallet, A-S ^{[6
]}

Hillmen, P. ^{[7
]}

Duerig, J. ^{[8
]}

Gregory, S. A. ^{[9
]}

Kalaycio, M. ^{[10
]}

Aurran-Schleinitz, T. ^{[11
]}

Trentin, L. ^{[12
]}

Gribben, J. G. ^{[13
]}

Chanan-Khan, A. ^{[14
]}

Purse, B. ^{[15
]}

Zhang, J. ^{[15
]}

De Bedout, S. ^{[16
]}

Mei, J. ^{[15
]}

Hallek, M. ^{[3
,17
]}

Stilgenbauer, S. ^{[1
]}

机构：

[1] Univ Ulm, Dept Internal Med 3, Albert Einstein Allee 23, D-89081 Ulm, Germany

[2] Univ Munich, Acad Teaching Hosp, Klinikum Schwabing, Munich, Germany

[3] Univ Cologne, Dept Internal Med 1, D-50931 Cologne, Germany

[4] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[5] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada

[6] Ctr Hosp Lyon Sud, Hosp Civils Lyon, Lyon, France

[7] St Jamess Inst Oncol, Leeds, W Yorkshire, England

[8] Univ Hosp Essen, Essen, Germany

[9] Rush Univ, Med Ctr, Chicago, IL 60612 USA

[10] Cleveland Clin, Cleveland, OH 44106 USA

[11] Inst J Paoli I Calmettes, F-13009 Marseille, France

[12] Univ Padua, Sch Med, Padua, Italy

[13] Univ London, Barts Canc Inst, London, England

[14] Mayo Clin, Jacksonville, FL 32224 USA

[15] Celgene Corp, Summit, NJ USA

[16] Celgene Corp, Boudry, Switzerland

[17] Cologne Cluster Excellence Cellular Stress Respon, Cologne, Germany

来源：

BLOOD CANCER JOURNAL | 2016年 / 6卷

关键词：

SURVIVAL; EFFICACY; CLL;

D O I：

10.1038/bcj.2016.9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Efficacy of lenalidomide was investigated in 103 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated on the prospective, multicenter randomized phase-II CLL-009 trial. Interphase cytogenetic and mutational analyses identified TP53 mutations, unmutated IGHV, or del(17p) in 36/96 (37.5%), 68/88 (77.3%) or 22/92 (23.9%) patients. The overall response rate (ORR) was 40.4% (42/104). ORRs were similar irrespective of TP53 mutation (36.1% (13/36) vs 43.3% (26/60) for patients with vs without mutation) or IGHV mutation status (45.0% (9/20) vs 39.1% (27/68)); however, patients with del(17p) had lower ORRs than those without del(17p) (21.7% (5/22) vs 47.1% (33/70); P = 0.049). No significant differences in progression-free survival and overall survival (OS) were observed when comparing subgroups defined by the presence or absence of high-risk genetic characteristics. In multivariate analyses, only multiple prior therapies (>= 3 lines) significantly impacted outcomes (median OS: 21.2 months vs not reached; P = 0.019). This analysis indicates that lenalidomide is active in patients with relapsed/refractory CLL with unfavorable genetic profiles, including TP53 inactivation or unmutated IGHV.

引用

页码：e404 / e404

页数：4

共 17 条

[1] Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia [J].

Badoux, Xavier C. ;

Keating, Michael J. ;

Wen, Sijin ;

Lee, Bang-Ning ;

Sivina, Mariela ;

Reuben, James ;

Wierda, William G. ;

O'Brien, Susan M. ;

Faderl, Stefan ;

Kornblau, Steven M. ;

Burger, Jan A. ;

Ferrajoli, Alessandra .

BLOOD, 2011, 118 (13) :3489-3498

[2] IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia [J].

Bulian, Pietro ;

Rossi, Davide ;

Forconi, Francesco ;

Del Poeta, Giovanni ;

Bertoni, Francesco ;

Zucca, Emanuele ;

Montillo, Marco ;

Pozzato, Gabriele ;

D'Arena, Giovanni ;

Efremov, Dimitar G. ;

Marasca, Roberto ;

Lauria, Francesco ;

Gaidano, Gianluca ;

Gattei, Valter ;

Laurenti, Luca .

JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10

[3] Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Shaw, Yun ;

Bilotti, Elizabeth ;

Zhou, Cathy ;

James, Danelle F. ;

O'Brien, Susan .

BLOOD, 2015, 125 (16) :2497-2506

[4] Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study [J].

Chanan-Khan, Asher ;

Miller, Kena C. ;

Musial, Laurie ;

Lawrence, David ;

Padmanabhan, Swaminathan ;

Takeshita, Kenichi ;

Porter, Carl W. ;

Goodrich, David W. ;

Bernstein, Zale P. ;

Wallace, Paul ;

Spaner, David ;

Mohr, Alice ;

Byrne, Catriona ;

Hernandez-Ilizaliturri, Francisco ;

Chrystal, Cynthia ;

Starostik, Petr ;

Czuczman, Myron S. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5343-5349

[5] Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia [J].

Chen, Christine I. ;

Bergsagel, P. Leif ;

Paul, Harminder ;

Xu, Wei ;

Lau, Anthea ;

Dave, Nimisha ;

Kukreti, Vishal ;

Wei, Ellen ;

Leung-Hagesteijn, Chungyee ;

Li, Zhi Hua ;

Brandwein, Joseph ;

Pantoja, Mariela ;

Johnston, James ;

Gibson, Spencer ;

Hernandez, Tiffany ;

Spaner, David ;

Trudel, Suzanne .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) :1175-1181

[6] Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53 [J].

Fecteau, Jessie-F. ;

Corral, Laura G. ;

Ghia, Emanuela M. ;

Gaidarova, Svetlana ;

Futalan, Diahnn ;

Bharati, Ila Sri ;

Cathers, Brian ;

Schwaederle, Maria ;

Cui, Bing ;

Lopez-Girona, Antonia ;

Messmer, Davorka ;

Kipps, Thomas J. .

BLOOD, 2014, 124 (10) :1637-1644

[7] Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia [J].

Ferrajoli, Alessandra ;

Lee, Bang-Ning ;

Schlette, Ellen J. ;

O'Brien, Susan M. ;

Gao, Hui ;

Wen, Sijin ;

Wierda, William G. ;

Estrov, Zeev ;

Faderl, Stefan ;

Cohen, Evan N. ;

Li, Changping ;

Reuben, James M. ;

Keating, Michael J. .

BLOOD, 2008, 111 (11) :5291-5297

[8] Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines [J].

Hallek, Michael ;

Cheson, Bruce D. ;

Catovsky, Daniel ;

Caligaris-Cappio, Federico ;

Dighiero, Guillaume ;

Doehner, Hartmut ;

Hillmen, Peter ;

Keating, Michael J. ;

Montserrat, Emili ;

Rai, Kanti R. ;

Kipps, Thomas J. .

BLOOD, 2008, 111 (12) :5446-5456

[9] How does lenalidomide target the chronic lymphocytic leukemia microenvironment? [J].

Kater, Arnon P. ;

Tonino, Sanne H. ;

Egle, Alexander ;

Ramsay, Alan G. .

BLOOD, 2014, 124 (14) :2184-2189

[10] VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia [J].

Kröber, A ;

Seiler, T ;

Benner, A ;

Bullinger, L ;

Brückle, E ;

Lichter, P ;

Döhner, H ;

Stilgenbauer, S .

BLOOD, 2002, 100 (04) :1410-1416

← 1 2 →